NASDAQ:IDXX - IDEXX Laboratories Stock Price, Price Target & More

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories declared that its Board of Directors has initiated a share buyback program on Sunday, June 4th 2017, which allows the company to buyback 3,000,000 outstanding shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Stock buyback programs are often an indication that the company's leadership believes its stock is undervalued.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings data on Friday, May, 4th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.92 by $0.09. The company earned $537.60 million during the quarter, compared to the consensus estimate of $525.14 million. IDEXX Laboratories had a negative return on equity of 530.24% and a net margin of 13.87%. IDEXX Laboratories's quarterly revenue was up 16.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.77 earnings per share. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories issued an update on its FY18 earnings guidance on Friday, May, 4th. The company provided earnings per share (EPS) guidance of $4.06-4.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.11. The company issued revenue guidance of +12-14% to ~$2.205-2.245 billion, compared to the consensus revenue estimate of $2.22 billion.

7 equities research analysts have issued 12-month target prices for IDEXX Laboratories' shares. Their forecasts range from $200.00 to $260.00. On average, they anticipate IDEXX Laboratories' stock price to reach $222.8333 in the next twelve months. This suggests that the stock has a possible downside of 10.2%. View Analyst Ratings for IDEXX Laboratories.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to IDEXX Laboratories include IPSEN S A/S (IPSEY), Immunomedics (IMMU), Neogen (NEOG), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX) and Vermillion (VRML).

Headlines about IDXX stock have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. IDEXX Laboratories earned a news impact score of 0.14 on Accern's scale. They also gave news coverage about the company an impact score of 45.45 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

IDEXX Laboratories' stock is owned by many different of retail and institutional investors. Top institutional investors include American Capital Management Inc. (0.57%), Welch & Forbes LLC (0.21%), Davis R M Inc. (0.20%), Bank of Montreal Can (0.19%), Chicago Capital LLC (0.12%) and Franklin Street Advisors Inc. NC (0.06%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including American Capital Management Inc., Davis R M Inc., Hartford Investment Management Co., Calamos Advisors LLC, CenturyLink Investment Management Co, Welch & Forbes LLC, Spence Asset Management and Tokio Marine Asset Management Co. Ltd.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Rebecca M Henderson and William T End. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Westpac Banking Corp, Bank of Montreal Can, Franklin Street Advisors Inc. NC, First Citizens Bank & Trust Co., State of Alaska Department of Revenue, V Wealth Management LLC and NN Investment Partners Holdings N.V.. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $248.14.

IDEXX Laboratories has a market capitalization of $20.77 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. IDEXX Laboratories employs 7,600 workers across the globe.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]